Beckman Coulter Diagnostics Earns CE Mark for New Assay Delivering Bacterial vs. Viral Infection Results in Approximately 20 Minutes
Rhea-AI Summary
Beckman Coulter Diagnostics (NYSE:DHR) received CE 2797 mark under IVDR on April 13, 2026 for the Access MeMed BV assay, enabling bacterial vs. viral differentiation in about 20 minutes on DxI 9000 and Access 2 analyzers across Europe.
The assay is supported by clinical studies and real‑world data showing up to 99% NPV and clinician impact in 82–87% of cases; independent modeling estimates up to €80 million in avoidable European healthcare costs through fewer unnecessary admissions and testing.
AI-generated analysis. Not financial advice.
Positive
- CE 2797 IVDR clearance enables European market access
- Assay runs on existing DxI 9000 and Access 2 analyzers
- ~20 minute bacterial vs viral differentiation at high throughput
- Modeling indicates potential up to €80M avoidable costs saved
Negative
- Projected €80M savings are based on independent modeling, not guaranteed outcomes
- Regulatory clearance is a CE mark, so initial availability targets Europe
- Clinical and economic benefits depend on adoption and local care pathways
News Market Reaction – DHR
On the day this news was published, DHR gained 3.30%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
DHR fell 1.75% while key diagnostics peers also traded lower (e.g., TMO -0.8%, IDXX -2.88%, LH -4.42%), but no names appeared on the momentum scanner, suggesting a stock-specific move rather than a strong sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 20 | Earnings call schedule | Neutral | +0.3% | Announcement of Q1 2026 earnings conference call timing and webcast details. |
| Feb 24 | Dividend declaration | Positive | +0.2% | Quarterly cash dividend of $0.40 per share with set record and payment dates. |
| Feb 24 | Conference presentation | Neutral | +0.2% | CEO presentation scheduled at TD Cowen Healthcare Conference with webcast access. |
| Feb 17 | Acquisition terms | Positive | -2.9% | Agreement to acquire Masimo for $180 per share, totaling $9.9B in cash. |
| Feb 17 | Acquisition strategy | Positive | -2.9% | Detailed Masimo deal metrics, projected EBITDA, synergies, and EPS accretion. |
Routine items like dividends, conferences, and earnings calls have coincided with small gains, while larger strategic moves such as the Masimo acquisition saw negative price reactions despite positive framing.
Recent news for Danaher shows a mix of routine corporate updates and major strategic moves. An earnings call announcement on Mar 20, 2026 and a quarterly dividend declaration of $0.40 per share on Feb 24, 2026 both aligned with modest gains. Conference participation also saw slight positive moves. In contrast, the twin announcements on Feb 17, 2026 detailing the Masimo acquisition for about $9.9 billion coincided with a -2.93% reaction, indicating investor caution toward large M&A. Today’s diagnostics assay news fits the company’s focus on innovation within its Diagnostics segment.
Market Pulse Summary
This announcement highlights Danaher’s diagnostics arm gaining IVDR CE-marked access for the MeMed BV assay, delivering bacterial versus viral results in about 20 minutes and modeled savings of up to €80M across European systems. Real-world data in nearly 6,000 patients and up to 99% NPV reinforce clinical utility. In the broader context of recent Masimo acquisition plans and steady dividends, investors may watch adoption rates, reimbursement dynamics, and integration within Danaher’s Diagnostics portfolio.
Key Terms
ce mark regulatory
ivdr regulatory
immunoassay analyzers medical
host-response test medical
antimicrobial stewardship medical
negative predictive value medical
community-acquired pneumonia medical
lower respiratory tract infections medical
AI-generated analysis. Not financial advice.
Modeling Shows Adoption of New Access MeMed BV Assay Could Cut up to
Validated for use across Beckman Coulter's installed base of DxI 9000 and Access 2 immunoassay analyzers, the Access MeMed BV assay enables fast, reliable infection differentiation while leveraging laboratories' existing infrastructure and workflows. Beckman Coulter partnered with MeMed, a leader in advanced host‑response technologies, to bring the proven MeMed BV® test into core laboratory settings. The MeMed BV test has been shown to enhance clinical decision‑making, support clinicians in curbing unnecessary antibiotic use, and advance antimicrobial‑stewardship initiatives—results reinforced by strong clinical studies and real‑world performance data.1-7
Published MeMed economic data, together with incidence estimates for lower respiratory tract infections (LRTI) and community‑acquired pneumonia (CAP), indicate that European healthcare systems shoulder significant avoidable costs each year.8-10 With Access MeMed BV now available on Beckman Coulter's extensive installed base across
"By delivering rapid, highly reliable bacterial and viral differentiation on routine immunoassay systems, we're empowering care teams with the timely insights they need to guide appropriate treatment decisions, while optimizing laboratory efficiency using existing workflows," said Melissa Naiman, Medical & Scientific Affairs at Beckman Coulter Diagnostics."
"This collaboration with Beckman Coulter significantly accelerates our mission to make host-response testing available at scale," said Eran Eden, CEO & Co-founder, MeMed. "The MeMed BV test has repeatedly demonstrated its ability to improve clinical decision making, empower clinicians to reduce unnecessary antibiotic use, and support antimicrobial stewardship, backed by robust clinical and real-world evidence. Making the assay available on high-throughput laboratory analyzers allows healthcare systems to unlock those benefits for far more patients."
Fast Insights Guides Confident Clinical Decisions
Bacterial and viral infections frequently present with similar symptoms, making early differentiation challenging and sometimes leading to inappropriate patient management or unnecessary antibiotic use. Early distinction is critical because clinicians often must prescribe treatment before traditional diagnostic methods—which can take hours or days—to deliver definitive results. The Access MeMed BV assay provides actionable bacterial vs. viral insights in approximately 20 minutes, using Beckman Coulter immunoassay analyzers to generate rapid results at scale.
Recent real-world studies across nearly 6,000 adult and pediatric patients found that clinicians face uncertainty about antibiotic prescribing in approximately 16–
Reducing Costs, Hospitalizations, and Unnecessary Antibiotic Use at Scale
Challenges in accurately identifying bacterial versus viral infections early can drive downstream healthcare costs, unnecessary admissions, and repeat testing. Independent health‑economic modeling highlights the potential value of incorporating MeMed BV into routine care.10
For every 1,000 patients evaluated for suspected community-acquired pneumonia (CAP), incorporating MeMed BV into clinical decision-making‑ generated substantial efficiencies. In adults, the model showed
About Access MeMed BV Assay
The Access MeMed BV Assay is a diagnostic test indicated for use in patients presenting to a medical center and inpatients with suspected acute bacterial or viral infection. The test integrates measurements of three key host-immune proteins (TRAIL, IP-10, and CRP) into a score indicating the likelihood of bacterial or viral infections.
About Beckman Coulter. Inc.
A global leader in advanced diagnostics, Beckman Coulter Diagnostics has challenged convention to elevate the diagnostic laboratory's role in improving patient health for more than 90 years. Our mission is to Relentlessly Reimagine Healthcare, One Diagnosis at a Time – and we do this by applying the power of science, technology and the passion and creativity of our teams. Our diagnostic solutions are used in complex clinical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. We exist to deliver smarter, faster diagnostic solutions that move the needle forward from what's now to what's next. We do this by accelerating care with an extensive clinical menu, scalable lab automation technologies, insightful clinical informatics, and optimize lab performance services. Beckman Coulter is part of the Danaher Corporation (NYSE:DHR) family of global science and technology companies. Headquartered in
Follow and connect with Beckman Coulter via LinkedIn, Twitter, and Facebook.
ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them.
Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow.
© 2026 Beckman Coulter. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in
1 Singer et al. 2025. Effect of host-protein test (TRAIL/IP-10/CRP) on antibiotic prescription and emergency department or urgent care center return visits: the JUNO pilot randomized controlled trial. Academic Emergency Medicine Journal.
2 LoVerde et al. 2025. Real-world study assessing sensitivity and clinical utility of a host-protein test in adult emergency departments patients with blood culture ordered. JACEP Open.
3 Kalmovich B. et al. 2023. Impact on patient management of a novel host response test for distinguishing bacterial from viral infections: real world evidence from the urgent care setting. Biomedicines.
4 Kalmovich B. et al. 2025. Implementation of a rapid host-protein diagnostic test for distinguishing bacterial and viral infections in adults presenting to urgent care centers: a pragmatic cohort study. BMC Medicine.
5 Kalmovich B. et al. 2025. Use of a host-protein test for pediatric acute infections at urgent care centers. Pediatrics.
6 Diamantopoulou P. et al. 2026. Real-world utility of the host-response MeMed BV test in a pediatric emergency department: A non-randomized study with optimized antimicrobial and diagnostic stewardship. Children.
7 van Houten C.B. et al. 2016. A host-protein based assay to differentiate between bacterial and viral infections in preschool children (OPPORTUNITY): a double-blind, multicentre, validation study. Lancet Infectious Diseases.
8 Bender R. et al. 2024. Global, Regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the global burden of disease study 2021.
9 Reyes L.F. et al. 2025. Community-acquired pneumonia. The Lancet.
10 Gregg E. et al. 2025. Host-response testing with MeMed BV in community-acquired pneumonia: an economic evaluation from the
11 Bachur R.G. et al. 2024. A rapid host-protein test for differentiating bacterial from viral infection: Apollo diagnostic accuracy study. JACEP Open.
12 Allen C. et al. 2025. Development of a reference standard to assign bacterial versus viral infection etiology using an all-inclusive methodology for comparison of novel diagnostic tool performance. Clinical Infectious Diseases.
13 Papan C. et al. 2022. A host signature based on TRAIL, IP-10, and CRP for reducing antibiotic overuse in children by differentiating bacterial from viral infections: a prospective, multicentre cohort study.
View original content to download multimedia:https://www.prnewswire.com/news-releases/beckman-coulter-diagnostics-earns-ce-mark-for-new-assay-delivering-bacterial-vs-viral-infection-results-in-approximately-20-minutes-302740015.html
SOURCE Beckman Coulter Diagnostics